Abstract P5-12-03: Genome copy number entropy as predictor of response for neoadjuvant therapy in early breast cancer

Autor: Arrate Plazaola, Lourdes Calvo, Agust Barnadas, Eva Carrasco, Jose Ignacio Chacon, Federico Rojo, Angela Santonja, A. Lluch, Oscar M. Rueda, Rosalia Caballero, Emiliano Zamora de Alba, Massimo Chiesa, S-F Chin, J. de la Haba-Rodríguez, Jesús Herranz, A. Arcusa, Nuria Ribelles, B Cirauqul, Pedro Sánchez-Rovira, M. Ramos, Begoña Bermejo, C Caldas, Joan Albanell

Publikováno v: Cancer Research. 79:P5-12

Background Copy Number Alterations (CNAs) represent changes in the copy number of genomic segments of somatic cells due to chromosomal instability. CNAs include gene amplifications or deletions and can be involved in tumorigenesis. We analyzed CNAs d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::01a8a67636337c6d56476049fa9e616c
https://doi.org/10.1158/1538-7445.sabcs18-p5-12-03

Abstract GS2-04: Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer

Autor: Roberto Torres, P López-Álvarez, Carlos Sampaio, Carlos Barrios, E Villar, Eva Carrasco, A. Lluch, L Pérez-Michel, J.G.M. Segalla, S. Reyes, JA Garcia-Saenz, J. Cárdenas, Maria Jose Godes, M. Ramos, J Castellanos, A. Ruiz, M. J. Escudero, E Martínez de Dueñas, Lourdes Calvo, J Moncayo, J. M. Baena, Manuel Ruiz-Borrego, J. Vinholes, L Torrecillas, Susana Bezares, M. Martin, Henry L. Gomez, Agust Barnadas, M. A. Seguí, Antonio Llombart, Gilberto Luiz da Silva Amorim, J. Bines, Álvaro Rodríguez-Lescure, M Rodríguez de la Borbolla, Antonio Antón, J de la Haba, B Cardemil, E Garcia

Publikováno v: Cancer Research. 79:GS2-04

Background: Triple negative breast cancers (TNBC) have a greater risk of relapse than non-TNBC. New therapeutic approaches are needed for these patients (pts). CIBOMA/2004-01_GEICAM/2003-11 is a multinational, randomized phase III trial exploring adj

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b0aebf64b3256301578ee24865dcc030
https://doi.org/10.1158/1538-7445.sabcs18-gs2-04

1719P Clinical characteristics and 28-day mortality among patients with solid cancers and COVID-19 in a tertiary hospital

Autor: Jose Carlos Tapia, J. Gavira, M. Riudavets, Margarita Majem, Ignasi Gich, Oscar J. Ponce, Agust Barnadas

Publikováno v: Europe PubMed Central
Annals of Oncology

Background: The impact of coronavirus disease 2019 (COVID-19) on cancer patients is still unknown We aimed to describe the clinical characteristics and 28-day mortality among patients with solid cancers (SC) and COVID-19 Methods: This single-center r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a28afe8b7c01626d80ccd79c4a6632e6
https://doi.org/10.1016/j.annonc.2020.08.1783

Interim results from CompLEEment-1 (A phase IIIb study of ribociclib and letrozole as first-line therapy for advanced breast cancer in an expanded population): Spanish cohort results

Autor: Noraida Horta Díaz, M. Martin, R. De Toro, Eva Ciruelos, Fernando Salvador Moreno, Blanca Cantos, R. Villanueva Vazquez, Vanesa Quiroga, J de la Haba, Antonio Antón, B. Jiménez-Rodríguez, I. Álvarez, I. Delgado Mingorance, Santiago González-Santiago, Javier Salvador, E. Vicente, Agust Barnadas, Nerea Martinez, L. De La Cruz, M. Bellet Ezquerra

Publikováno v: Annals of Oncology. 30:v119-v120

Background In Spain luminal metastatic Breast Cancer accounts for more than 3000 deaths yearly. Ribociclib+letrozole has shown efficacy on prolonging progression free survival (PFS) vs placebo+letrozol in two phase 3 trials. However, data on efficacy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8e96e4991f301927c7c850f9491e3461
https://doi.org/10.1093/annonc/mdz242.031

A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

Autor: Francisco Ayala, Carlos A. Rodriguez, Lourdes Calvo, A. Lluch, Andrés Redondo, Agust Barnadas, A. González, Antonio Antón, J. de la Haba, Antonio Llombart, J. M. López-Vega, Eva Ciruelos, Joan Albanell, Javier Cortes, Isabel Alvarez, I. Peláez, E. Aba, Montse Muñoz, Á. Rodríguez, A. Ruiz, Eduardo Martínez

Publikováno v: CLINICAL & TRANSLATIONAL ONCOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón
Clinical & Translational Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA

To converge on an expert opinion to define aggressive disease in patients with HER2-negative mBC using a modified Delphi methodology. A panel of 21 breast cancer experts from the Spanish Society of Medical Oncology agreed upon a survey which comprise

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::affefa4d038e1bdfd6683e8805500cd2
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1585